Diaz-Ordoñez Lorena, Duque-Cordoba Paola Andrea, Silva-Cuero Katherine, Gutierrez-Medina Juan David, Saldarriaga Wilmar, Murgašová Lenka, Magner Martin, Candelo Estephania, Pachajoa Harry
Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras (CIACER), Universidad Iccesi, Cali, Colombia.
Departamento de Ciencias Básicas Médicas, Facultad de Salud, Universidad Icesi, Cali, Colombia.
Medicine (Baltimore). 2025 Jan 10;104(2):e41128. doi: 10.1097/MD.0000000000041128.
Hearing impairment is a prevalent clinical feature in Morquio syndrome (mucopolysaccharidosis IVA or MPS IVA) patients, often presenting in diverse forms: conductive, sensorineural, or a combination known as mixed hearing loss. The mixed form entails a blend of both conductive and sensorineural elements, typically exhibiting a progressive trajectory. This scoping review aimed to comprehensively analyze available evidence pertaining to the pathophysiology, classification, epidemiology, and clinical management of hearing loss in individuals with MPS IVA.
Targeted literature was searched using MEDLINE, Literatura Latino-Americana e do Caribe em Ciências da Saúde, Web of Science, the Cochrane Library, Trip Medical Database, Embase, ScienceDirect, and Google Scholar, with a second search cycle to identify gray literature. A systematic search strategy using Medical Subject Headings keywords was implemented: "Hearing Disorders" OR "Hearing Loss" AND "Mucopolysaccharidosis IV" or "Hearing Disorders" OR "Hearing Loss" AND "Mucopolysaccharidosis IV." The identified bibliography was uploaded to COVIDENCE platform for information management. Articles were screened by 3 independent reviewers following the eligibility criteria.
Twenty-seven articles met the inclusion criteria, spanning information from 568 patients across 16 different countries. None of the studies had complete epidemiological information. Only 2 studies provided sufficient data to address the pathophysiology, while 3 addressed management and treatment. Hearing loss was reported in 210 of 568 patients. A total of 19.2% of patients reported recurrent ear infections. None of the studies reported vertigo, tinnitus, or dizziness in the patients. Pure-tone audiometry was the primary test used to diagnose and monitor auditory impairment in patients with Morquio syndrome.
Five hundred sixty-eight patients with MPS IVA were identified, of whom 210 (37%) developed hearing loss, the most common of which was moderate. Despite the lack of information on the diagnosis and management of hearing loss in Morquio syndrome, this study found that approximately one-third of participants exhibited some form of auditory impairment, with the majority of these cases being sensorineural in nature.
听力障碍是莫尔基奥综合征(黏多糖贮积症IVA型或MPS IVA)患者的常见临床特征,通常有多种表现形式:传导性、感音神经性或两者皆有的混合性听力损失。混合性形式兼具传导性和感音神经性因素,通常呈进行性发展。本综述旨在全面分析与MPS IVA患者听力损失的病理生理学、分类、流行病学及临床管理相关的现有证据。
通过MEDLINE、拉丁美洲及加勒比地区卫生科学文献数据库、科学网、考克兰图书馆、Trip医学数据库、Embase、ScienceDirect和谷歌学术搜索目标文献,并进行第二轮检索以识别灰色文献。采用医学主题词关键词实施系统检索策略:“听力障碍”或“听力损失”与“黏多糖贮积症IV型”或“听力障碍”或“听力损失”与“黏多糖贮积症IV”。将识别出的参考文献上传至COVIDENCE平台进行信息管理。由3名独立评审员根据纳入标准筛选文章。
27篇文章符合纳入标准,涵盖来自16个不同国家568例患者的信息。没有一项研究具备完整的流行病学信息。仅有2项研究提供了足够的数据来阐述病理生理学,3项研究涉及管理和治疗。568例患者中有210例报告有听力损失。共有19.2%的患者报告有复发性耳部感染。没有研究报告患者出现眩晕、耳鸣或头晕。纯音听力测定是用于诊断和监测莫尔基奥综合征患者听觉障碍的主要检测方法。
共识别出568例MPS IVA患者,其中210例(37%)出现听力损失,最常见的为中度听力损失。尽管缺乏关于莫尔基奥综合征听力损失诊断和管理的信息,但本研究发现约三分之一的参与者存在某种形式的听觉障碍,其中大多数病例为感音神经性。